A core, overlooked element of the Biohub's success is physically bringing together scientists and engineers from competing universities like Stanford, UCSF, and Berkeley. This simple act of co-location dismantled institutional barriers and fostered a level of collaboration that was previously uncommon.

While lacking investor density, cities like Houston thrive by tapping into world-class academic medical centers (e.g., MD Anderson) for talent and collaborations. Furthermore, significant state-level funding, like Texas's CPRIT, can bridge the early-stage capital gap often filled by local VCs in major hubs.

Instead of being standalone institutes, CZI's Biohubs in San Francisco, Chicago, and New York are deeply integrated with elite universities like Stanford, Northwestern, and Columbia. This strategic model provides immediate access to world-class talent, research infrastructure, and collaborative opportunities, forming the "magic of the model."

While large pharmaceutical companies are filled with a wide breadth of smart people, smaller biotech firms offer a different kind of intellectual environment. They feature the same degree of brilliance, but it's concentrated in a much more focused organization, creating a unique depth of talent.

CZI's Biohub model hinges on a simple principle: physically seating biologists and engineers from different institutions (Stanford, UCSF, Berkeley) together. This direct proximity fosters collaboration and creates hybrid experts, overcoming the institutional silos often reinforced by traditional grant-based funding.

Responding to Wall Street pressure to de-risk, large pharmaceutical firms cut internal early-stage research. This led to an exodus of talent and the rise of contract research organizations (CROs), creating an infrastructure that, like cloud computing for tech, lowered the barrier for new biotech startups.

Founded in Minnesota, Cellcuity taps the University of Minnesota and the region's medical device industry for scientific talent. For specialized roles like clinical development, it embraces a distributed team, demonstrating a viable model for building a biopharma company outside of traditional hubs.

Thriving life sciences ecosystems in Ireland, the UK, and Massachusetts did not grow by accident. Their success is the result of deliberate, long-term government strategies, including tax incentives, shared R&D infrastructure like the UK's 'Catapult' network, and fostering deep connections between technology, hospitals, and capital.

Michal Preminger reflects that her former company, located outside a major biotech hub, had to invent solutions in isolation. It lacked the mentorship and deep market and business wisdom that permeates ecosystems like Boston, which would have accelerated its progress.